United Therapeutics (UTHR) shares have quietly outperformed the pharma and biotech sector in the past three months, gaining nearly 48%. The company’s steady revenue and net income growth raise questions about whether this momentum can continue.

See our latest analysis for United Therapeutics.

United Therapeutics’ 48% share price return over the past three months has pushed its stock near the top of the pharma and biotech sector this quarter, building on its longer-term momentum. The company’s three-year total shareholder return now stands at an impressive 98%. Performance like this suggests that investors may be reassessing the company’s growth prospects and risk profile following another stretch of robust financial results.

If…